Promising combo aims to shrink tumors in elderly breast cancer patients
NCT ID NCT07589972
First seen May 20, 2026 · Last updated Jun 22, 2026 · Updated 3 times
Summary
This study tests a combination of targeted drugs (trastuzumab and pertuzumab) plus a low-dose chemotherapy (vinorelbine) given before surgery to elderly patients (70+) with HER2-positive breast cancer. The goal is to see if this approach can completely eliminate cancer cells in the breast and lymph nodes. The trial will enroll 45 participants and monitor how well the tumors respond, with a focus on safety and effectiveness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY IN ELDERLY HER2-POSITIVE BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
trastuzumab, pertuzumab, and vinorelbine
What this could lead to
If successful, this could offer a less toxic, effective pre-surgery treatment option for elderly patients with HER2-positive breast cancer, potentially improving outcomes without harsh side effects.
What could go wrong
This is a small, early-phase study with only 45 participants, so results may not apply broadly. The treatment may not work for everyone, and side effects from the chemotherapy and targeted drugs are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.